An2 Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: BML Investment Partners Significantly Reduces Stake in AN2 Therapeutics, Now Holds 1.4%
BML Investment Partners, L.P. has filed an amended Schedule 13D, revealing a substantial reduction in its beneficial ownership of AN2 Therapeutics, Inc. common stock to 1.4% after a series of sales in May and June 2025.
NASDAQ
BML Investment Partners, L.P. has filed an amended Schedule 13D, disclosing a reduction in its beneficial ownership of AN2 Therapeutics, Inc. common stock to 10.7% following recent sales.
NASDAQ
SCHEDULE 13D: Activist Investor Demands Liquidation or Sale of AN2 Therapeutics After Lead Drug Failure
BML Investment Partners, holding 19.1% of AN2 Therapeutics, has filed a Schedule 13D advocating for an orderly winddown, liquidation, and capital return to shareholders following the Phase 3 failure of the company's lead drug, EBO-301.